{"id":35462,"date":"2020-12-18T16:21:57","date_gmt":"2020-12-18T16:21:57","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35462"},"modified":"2023-05-10T13:10:43","modified_gmt":"2023-05-10T12:10:43","slug":"miriam-bujny","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/miriam-bujny\/","title":{"rendered":"Miriam Bujny"},"content":{"rendered":"
\n\n\t

Miriam Bujny<\/h2>\n

Chief Development Officer (CDO) at Sapreme Technologies BV<\/h4>\n\t

Miriam joined Sapreme as CDO in 2020. She is an experienced translational science lead with background in RNA and antibody therapeutics, and uses this background at Sapreme to drive the development of next-generation macromolecules that circumvent endosomal entrapment. Over the last ten years, Miriam has held leadership positions in various drug discovery and clinical development roles. As head of the Translational Science department and Senior Director R&D at ProQR Therapeutics, she recently led early development activities for ProQR’s RNA therapy programs.<\/p>\n

From 2012 to 2016, she worked in various roles for Janssen, including anti-viral antibody therapy development. From 2010 to 2012, Miriam worked at Crucell, before its acquisition by Johnson & Johnson, in the Innovation & Discovery Labs on antibody discovery and engineering. Miriam holds a Ph.D. in biochemistry from the University of Bristol with a specialization in endosomal transport. She completed postdoctoral training in the lab of Dr. Xiaowei Zhuang at Harvard University.<\/p>\n\t\t\t\t\t\t\t\"Miriam_Bujny_Sapreme_Tecnhologies_BioTech_Pharma_Summit_2021_Porto_Profile_Gallery\"\t\t\t\t\t\t\t\n

\n\tTitle: Antibody-targeted cytoplasmic delivery of fusion proteins and antibody fragments using Sapreme’s endosomal escape enhancers\n\t<\/h3>\n\t
\n

The development of improved cancer therapeutics critically depends on addressing novel targets and pathways. The advent of large biobanks, next generation genomics and proteomics methods have yielded novel insights into initial driver and drug resistance associated mutations and suggested a number of novel targets. Unfortunately, most of these may not be amenable to the development of small molecule inhibitors. Many would be amenable to antibody-based interventions, such as i.e. in protein:protein interaction blocking, but their location in the cytoplasm or nucleus of the cell makes them inaccessible to such modalities. Other potential therapeutic interventions could consist of the delivery of protein toxins, or introduction of PPI decoys. Sapreme’s technologies allow multiple-log improvements in intracellular delivery efficiency of toxins and other proteins by enabling efficient scape from endosomal entrapment. This bioconjugation platform is compatible with validated targeting modalities such as antibodies, antibody fragment or smaller ligands, and lends itself well to integration with existing large-scale manufacturing methods. Here, we will present data demonstrating Sapreme SPT001 molecule can deliver pharmaceutically relevant amounts of bispecific antibodies and antibody fusion proteins to the cytoplasm in a tissue specific manner, and provide perspective on ongoing developments.<\/p>\n

KEY WORDS: <\/strong><\/p>\n